Transient apoptosis inhibition in donor cells increases efficacy of hematopoietic stem cell transplantation without increasing the risk of leukemogenesis
M Kollek, G Voigt, D Bertele, A Garcia, U Maurer, F Krombholz, V Labi, N Fischer, C Niemeyer, S Geley, A Villunger, M Erlacher · Klinische Pädiatrie · 2014 · Heft 05
Bibliografische Angaben
Zusammenfassung
Hematopoietic stem cell transplantation (HSCT) is still associated with several risks. Here, we propose to inhibit apoptosis in donor hematopoietic stem and progenitor cells (HSPC) to increase efficacy of HSCT and to lower the risk of graft failure or delayed engraftment. We have previously shown that the BH3-only proteins, Bim and Bmf play major roles in apoptosis induction of HSPC, and that inhibition of either protein is sufficient to increase donor cell survival during HSCT. However, for safety reasons (i.e. malignant transformation) apoptosis inhibition has to be transient when used therapeutically. We coul…
